Related Experiment Video

Updated: Feb 17, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.2K

Adjuvant therapy in renal cell carcinoma: does higher risk for recurrence improve the chance for success?

R A Figlin1, B C Leibovich2, G D Stewart3

  • 1Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, USA.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|November 30, 2017
PubMed

Insights

Adjuvant targeted therapies show promise for renal cell carcinoma patients post-surgery. Ongoing research aims to clarify conflicting data and optimize treatment for preventing tumor recurrence.

Area of Science:

  • Oncology
  • Nephrology
  • Pharmacology

Background:

  • Metastatic renal cell carcinoma (RCC) treatment success with targeted therapies (VEGF/mTOR inhibitors) prompted adjuvant setting investigation.
  • Early adjuvant targeted therapy trial results for RCC are emerging, with more expected soon.

Purpose of the Study:

  • To review adjuvant targeted therapy in RCC, interpreting current conflicting data.
  • To discuss future research directions, trial differences, and patient selection for adjuvant treatment.
  • To explore the role of radiology review and dose in treatment success and surrogate endpoints.

Main Methods:

  • Review of completed and ongoing adjuvant targeted therapy trials in renal cell carcinoma.
  • Analysis of factors influencing treatment success, including patient identification, radiology review, and dosage.
  • Discussion of disease-free survival as a surrogate endpoint and health benefit measurement.

Main Results:

  • Currently available data on adjuvant targeted therapy for RCC is conflicting.
  • Key differences exist between completed adjuvant targeted therapy trials.
  • Patient selection, blinded radiology review, and treatment dose are critical factors.

Conclusions:

  • Adjuvant targeted therapies require careful interpretation of existing data and further research.
  • Ongoing trials with targeted therapies and checkpoint inhibitors may enhance understanding of preventing RCC recurrence post-nephrectomy.
  • Optimizing patient selection and trial methodologies is crucial for future adjuvant treatment success.

More Related Videos

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.3K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

11.1K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
356
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
505
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.2K